Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 6/20 | 0.51 |
| ▸ | PGR | P06401 | 3/20 | 0.51 |
| ▸ | AR | P10275 | 2/20 | 0.51 |
| ▸ | TRPV1 | Q8NER1 | 12/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4368727 | 0.93 | NR3C1 (0.49) | NR3C1PGRARTRPV1 | |
| SCHEMBL4355542 | 0.93 | NR3C1 (0.51) | NR3C1PGRARTRPV1 | |
| SCHEMBL4360032 | 0.92 | NR3C1 (0.50) | NR3C1PGRARTRPV1 | |
| SCHEMBL4364989 | 0.90 | NR3C1 (0.53) | NR3C1PGRARTRPV1MEN1 | |
| SCHEMBL4369052 | 0.89 | NR3C1 (0.52) | NR3C1PGRARTRPV1 | |
| SCHEMBL4361219 | 0.89 | NR3C1 (0.48) | NR3C1PGRARTRPV1 | |
| SCHEMBL4363254 | 0.86 | NR3C1 (0.46) | NR3C1PGRARTRPV1 | |
| SCHEMBL4371575 | 0.84 | NR3C1 (0.54) | NR3C1PGRARTRPV1 | |
| SCHEMBL4356898 | 0.83 | NR3C1 (0.51) | NR3C1PGRARTRPV1 | |
| SCHEMBL4360527 | 0.82 | NR3C1 (0.52) | NR3C1PGRARTRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2072509-A1 | 1-Aryl-1H-quinoline-2-ones: process for their production and their use as anti-inflammatory agents | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-06-24 | — | — | EP | claimed |
| EP-2072509-A1 | 1-Aryl-1H-quinoline-2-ones: process for their production and their use as anti-inflammatory agents | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-06-24 | — | — | EP | disclosed |